Yang HJ, et al. World J Mens Health. 2023 Jan;41:e18. https://doi.org/10.5534/wjmh.220171

This study aimed to assess the prognostic value of computed tomography (CT)-attenuation and ¹⁸F-fluorodeoxyglucose (FDG) uptake of periprostatic adipose tissue (PPAT) for predicting disease progression-free survival (DPFS) in patients with prostate cancer. Seventy-seven patients with prostate cancer who underwent staging FDG positron emission tomography (PET)/CT were retrospectively reviewed. CT-attenuation (HU) and FDG uptake (SUV) of PPAT were measured from the PET/CT images. The relationships between these PPAT parameters and clinical factors were assessed, and a Cox proportional hazard regression test was performed to evaluate the prognostic significance of PPAT HU and SUV. PPAT HU and SUV showed significant positive correlations with tumor stage and serum prostate-specific antigen level (PSA) (p < 0.05). Patients with high PPAT HU and SUV had significantly worse DPFS than those with low PPAT HU and SUV (p < 0.05). In multivariate analysis, PPAT SUV was a significant predictor of DPFS after adjusting for tumor stage, serum PSA, and tumor SUV (p = 0.003; hazard ratio, 1.50; 95% confidence interval, 1.15–1.96). CT-attenuation and FDG uptake of PPAT showed significant association with disease progression in patients with prostate cancer. These imaging findings may be evidence of the role of PPAT in prostate cancer progression.

Background/Objectives: This study aimed to assess the diagnostic capability of quantitative parameters from whole-body bone single-photon emission computed tomography/computed tomography (SPECT/CT) in detecting bone metastases in prostate cancer patients; Methods: We retrospectively analyzed 82 prostate cancer patients who underwent staging bone scintigraphy with a full-ring 360° Cadmium-Zinc-Telluride (CZT) SPECT/CT system. From the SPECT/CT images, we measured the maximum (SUVmax) and mean (SUVmean) standardized uptake values at six normal bone sites (skull, humerus, thoracic spine, lumbar spine, iliac bone, and femur), and the SUVmax for both metastatic and benign bone lesions. Ratios of lesion SUVmax-to-maximum and mean uptake values at the skull, humerus, and femur were computed for each lesion; Results: SUVmax and SUVmean at the skull and femur exhibited significantly lower variance compared to those at the thoracic spine, lumbar spine, and iliac bone, and revealed no significant differences between patients with and without bone metastasis. In receiver operating characteristic curve analysis for detecting bone metastasis among 482 metastatic lesions, 132 benign bone lesions, and 477 normal bone sites, the lesion-to-femur mean uptake ratio demonstrated the highest area under the curve value (0.955) among SPECT/CT parameters. Using a cut-off value of 5.38, the lesion-to-femur mean uptake ratio achieved a sensitivity of 94.8% and a specificity of 86.5%; Conclusions: The bone lesion-to-femur mean uptake ratio was the most effective quantitative bone SPECT/CT parameter for detecting bone metastasis in prostate cancer patients. Quantitative analysis of bone SPECT/CT images could thus play a crucial role in diagnosing bone metastasis.

Asymptomatic bacteriuria (ASB) is defined as the presence of bacteria in the urine in the absence of urinary tract infection (UTI) symptoms. The prevalence of ASB increases with advancing age, particularly among older patients with underlying health conditions. ASB is especially common among residents of long-term care facilities; however, distinguishing ASB from symptomatic UTI in this population remains a significant clinical challenge. The frequent occurrence of ASB often results in unnecessary antibiotic administration, thereby contributing to the development of antibiotic resistance. Current clinical guidelines recommend screening for and treating ASB only in certain circumstances, such as prior to urological procedures or in pregnant women. There is a pressing need for improved diagnostic approaches to differentiate ASB more accurately from UTI, particularly in older adults. Reducing unnecessary urine testing and inappropriate antibiotic use may help prevent over-treatment and minimize associated risks, including Clostridium difficile infection and increased antimicrobial resistance.

Background Several approaches for urethral catheterization after the failure of initial urethral catheterization have been introduced. However, standard procedures regarding what should be done after failed conventional urethral catheterization have been not established. Therefore, we investigated the clinical efficacy of retrograde urethrography (RGU)-assisted urethral catheterization after failed conventional urethral catheterization. Methods Between July 2015 and July 2018, 136 patients who underwent RGU-assisted urethral catheterization after failed conventional urethral catheterization were included in this retrospective study. Patients’ clinical data, such as age, catheterization site, and previous history of urologic operations, were collected and assessed via chart review. Univariate and multivariate logistic regression analyses were performed to identify predictive factors for the failure of this procedure. Results Of the 136 patients, 94 (69.1%) experienced successful RGU-assisted urethral catheterization. Having a previous history of urologic operations, such as urethrotomy and transurethral prostatectomy, was identified as an independent predictive factor for the failure of RGU-assisted urethral catheterization (odds ratio = 9.453, 95% confidence interval = 2.703–33.063, p < 0.001). Conclusions RGU-assisted urethral catheterization can be one of the modalities for providing successful catheterization after failed conventional urethral catheterization. We believe that RGU-assisted urethral catheterization can be an effective procedure if patients have no previous history of urologic operations, such as urethrotomy and transurethral prostatectomy. Trial registration Soonchunhyang university institutional review board approval (No. 2018-08-021).